PrEP Persistence Support and Monitoring in Areas of High HIV Burden in the Midwestern United States

Overview

Journal AIDS Educ Prev

Specialties Infectious Diseases
Medical Education

Date 2023 Jul 6

PMID 37410372

Authors

Moira C McNulty

Jared Kerman

Samantha A Devlin

Maria Pyra

Laura Rusie

Kate Curoe

Liz Thompson

Joseph A Mason

Eleanor E Friedman

A Ziggy Uvin

C Hendricks Brown

John Schneider

Rupa Patel

Affiliations

Soon will be listed here.

Abstract

Monitoring pre-exposure prophylaxis (PrEP) metrics can guide service delivery yet does not occur routinely. We developed a survey to understand current practices for monitoring PrEP at PrEP-providing organizations in Illinois and Missouri. The survey was distributed from September through November 2020; 26 organizations participated. Most respondents indicated ongoing efforts to screen for PrEP eligibility (66.7%), link to care (87.5%), and retain clients in care (70.8%); 70.8% reported collecting data on PrEP initiation, 41.7% on retention in care, and 37.5% on missed visits. Barriers to monitoring PrEP metrics included lack of IT support (69.6%), manual processes (69.6%), and lack of staff resources (65.2%). Most respondents offered clients support for PrEP retention and adherence and wanted to expand interventions for PrEP persistence, yet fewer monitored corresponding metrics. To enhance PrEP implementation, organizations should improve monitoring and evaluation of PrEP metrics along the entire continuum and respond with appropriate services to support clients.

References

Dang M, Scheim A, Teti M, Quinn K, Zarwell M, Petroll A . Barriers and Facilitators to HIV Pre-Exposure Prophylaxis Uptake, Adherence, and Persistence Among Transgender Populations in the United States: A Systematic Review. AIDS Patient Care STDS. 2022; 36(6):236-248. PMC: 9242706. DOI: 10.1089/apc.2021.0236. View

Smith D, Van Handel M, Wolitski R, Stryker J, Hall H, Prejean J . Vital Signs: Estimated Percentages and Numbers of Adults with Indications for Preexposure Prophylaxis to Prevent HIV Acquisition--United States, 2015. MMWR Morb Mortal Wkly Rep. 2015; 64(46):1291-5. DOI: 10.15585/mmwr.mm6446a4. View

Rutstein S, Smith D, Dalal S, Baggaley R, Cohen M . Initiation, discontinuation, and restarting HIV pre-exposure prophylaxis: ongoing implementation strategies. Lancet HIV. 2020; 7(10):e721-e730. PMC: 7541752. DOI: 10.1016/S2352-3018(20)30203-4. View

Siegler A, Mouhanna F, Mera Giler R, Weiss K, Pembleton E, Guest J . The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis-to-need ratio in the fourth quarter of 2017, United States. Ann Epidemiol. 2018; 28(12):841-849. PMC: 6286209. DOI: 10.1016/j.annepidem.2018.06.005. View

Tookes H, Yao K, Chueng T, Butts S, Karsner R, Duque M . Pre-exposure prophylaxis access in federally qualified health centers across 11 United States metropolitan statistical areas. Int J STD AIDS. 2019; 30(10):978-984. PMC: 6854529. DOI: 10.1177/0956462419855178. View

Cohen M, Chen Y, McCauley M, Gamble T, Hosseinipour M, Kumarasamy N . Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011; 365(6):493-505. PMC: 3200068. DOI: 10.1056/NEJMoa1105243. View

Scott H, Spinelli M, Vittinghoff E, Morehead-Gee A, Hirozawa A, James C . Racial/ethnic and HIV risk category disparities in preexposure prophylaxis discontinuation among patients in publicly funded primary care clinics. AIDS. 2019; 33(14):2189-2195. PMC: 6832847. DOI: 10.1097/QAD.0000000000002347. View

Saberi P, Ming K, Scott H, Liu A, Steward W . "You can't have a PrEP program without a PrEP Coordinator": Implementation of a PrEP panel management intervention. PLoS One. 2020; 15(10):e0240745. PMC: 7567425. DOI: 10.1371/journal.pone.0240745. View

John S, Rendina H, Grov C, Parsons J . Home-based pre-exposure prophylaxis (PrEP) services for gay and bisexual men: An opportunity to address barriers to PrEP uptake and persistence. PLoS One. 2017; 12(12):e0189794. PMC: 5744975. DOI: 10.1371/journal.pone.0189794. View

10.

Chan P, Mena L, Patel R, Oldenburg C, Beauchamps L, Perez-Brumer A . Retention in care outcomes for HIV pre-exposure prophylaxis implementation programmes among men who have sex with men in three US cities. J Int AIDS Soc. 2016; 19(1):20903. PMC: 4908080. DOI: 10.7448/IAS.19.1.20903. View

11.

Pyra M, Haberer J, Hasen N, Reed J, Mugo N, Baeten J . Global implementation of PrEP for HIV prevention: setting expectations for impact. J Int AIDS Soc. 2019; 22(8):e25370. PMC: 6712462. DOI: 10.1002/jia2.25370. View

12.

Grant R, Lama J, Anderson P, McMahan V, Liu A, Vargas L . Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363(27):2587-99. PMC: 3079639. DOI: 10.1056/NEJMoa1011205. View

13.

Edeza A, Karina Santamaria E, Valente P, Gomez A, Ogunbajo A, Biello K . Experienced barriers to adherence to pre-exposure prophylaxis for HIV prevention among MSM: a systematic review and meta-ethnography of qualitative studies. AIDS Care. 2020; 33(6):697-705. DOI: 10.1080/09540121.2020.1778628. View

14.

Touger R, Wood B . A Review of Telehealth Innovations for HIV Pre-Exposure Prophylaxis (PrEP). Curr HIV/AIDS Rep. 2019; 16(1):113-119. DOI: 10.1007/s11904-019-00430-z. View

15.

Rowan S, Patel R, Schneider J, Smith D . Same-day prescribing of daily oral pre-exposure prophylaxis for HIV prevention. Lancet HIV. 2020; 8(2):e114-e120. DOI: 10.1016/S2352-3018(20)30256-3. View

16.

Fauci A, Redfield R, Sigounas G, Weahkee M, Giroir B . Ending the HIV Epidemic: A Plan for the United States. JAMA. 2019; 321(9):844-845. DOI: 10.1001/jama.2019.1343. View

17.

Smith D, Van Handel M, Grey J . Estimates of adults with indications for HIV pre-exposure prophylaxis by jurisdiction, transmission risk group, and race/ethnicity, United States, 2015. Ann Epidemiol. 2018; 28(12):850-857.e9. DOI: 10.1016/j.annepidem.2018.05.003. View

18.

Marcus J, Hurley L, Hare C, Nguyen D, Phengrasamy T, Silverberg M . Preexposure Prophylaxis for HIV Prevention in a Large Integrated Health Care System: Adherence, Renal Safety, and Discontinuation. J Acquir Immune Defic Syndr. 2016; 73(5):540-546. PMC: 5424697. DOI: 10.1097/QAI.0000000000001129. View

19.

Siegler A, Steehler K, Sales J, Krakower D . A Review of HIV Pre-exposure Prophylaxis Streamlining Strategies. Curr HIV/AIDS Rep. 2020; 17(6):643-653. PMC: 7671972. DOI: 10.1007/s11904-020-00528-9. View

20.

Stankevitz K, Grant H, Lloyd J, Gomez G, Kripke K, Torjesen K . Oral preexposure prophylaxis continuation, measurement and reporting. AIDS. 2020; 34(12):1801-1811. PMC: 8635251. DOI: 10.1097/QAD.0000000000002598. View